Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: GOSS

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Raymond James Maintains Outperform on Gossamer Bio, Lowers Price Target to $5

By Benzinga Newsdesk
December 7, 4:58 AM
Raymond James analyst Steven Seedhouse maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and lowers the price target from $15 to $5.

GOSS

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

SVB Leerink Maintains Outperform on Gossamer Bio, Lowers Price Target to $10

By Benzinga Newsdesk
December 7, 4:57 AM
SVB Leerink analyst Joseph Schwartz maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and lowers the price target from $15 to $10.

GOSS

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Dow Dips Over 500 Points; Nasdaq Down 2.5%

By Lisa Levin
December 6, 3:36 PM
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 2.5% on Tuesday.

BNED

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Price Target
  • Small Cap
  • Trading Ideas
  • Upgrades

Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis

By Vandana Singh
December 6, 2:19 PM
BTIG upgraded Aerovate Therapeutics Inc (NASDAQ:AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate’s…

AVTE

Read More
11 minute read
  • Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights
December 6, 1:22 PM
  Tuesday's session saw 167 companies set new 52-week lows.

ACHL

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Small Cap

S&P 500 Down Over 1%; Crude Oil Falls Sharply

By Lisa Levin
December 6, 1:05 PM
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 250 points on Tuesday.

AZRE

Read More
2 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Meta Platforms, Herbalife And Some Other Big Stocks Moving Lower On Tuesday

By Lisa Levin
December 6, 12:31 PM
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Tuesday. Here are some big stocks recording losses in today’s session.

APP

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation

By Vandana Singh
December 6, 11:00 AM
Gossamer Bio Inc (NASDAQ:GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension…

GOSS

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Gossamer Bio Announces Seralutinib Meets Primary Endpoint In Phase 2 TORREY Study In PAH

By Benzinga Newsdesk
December 6, 8:15 AM
- Primary Endpoint, Change in PVR at Week 24, Met with P-Value of 0.0310 - - Secondary Endpoint, Change in 6MWD, Numerically Favored Seralutinib - - Statistically Significant Improvements Observed in NT-proBNP and ECHO

GOSS

Read More
4 minute read
  • Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights
November 18, 2:17 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABBV

Posts pagination

Previous 1 … 4 5 6 7 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service